References
- Chung KF , Wenzel SE , Brozek JL . ERS/ATS task force on definition, evaluation and treatment of severe asthma. From the authors. Eur Respir J. 2014;44(1):267–268.
- Agache I , Akdis CA . Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine. Allergol Int. 2016;65(3):243–252. doi:https://doi.org/10.1016/j.alit.2016.04.011.
- Kolbeck R , Kozhich A , Koike M , et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353.e2.
- Takatsu K , Nakajima H . IL-5 and eosinophilia. Curr Opin Immunol. 2008;20(3):288–294. doi:https://doi.org/10.1016/j.coi.2008.04.001.
- Takatsu K . Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B. 2011;87(8):463–485.
- Molfino NA , Gossage D , Kolbeck R , Parker JM , Geba GP . Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy. 2012;42(5):712–737. doi:https://doi.org/10.1111/j.1365-2222.2011.03854.x.
- Walsh GM . Eosinophil apoptosis and clearance in asthma. J Cell Death. 2013;6:17–25.
- Bleecker ER , FitzGerald JM , Chanez P , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi: S0140-6736(16)31324-1.
- FitzGerald JM , Bleecker ER , Nair P , et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi: S0140-6736(16)31322-8 [pii].
- Nair P , Wenzel S , Rabe KF , et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458. doi:https://doi.org/10.1056/NEJMoa1703501.
- Castro M , Wenzel SE , Bleecker ER , et al. Benralizumab, an anti-interleukin 5 receptor? monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. The Lancet.Respiratory Medicine. 2014;2(11):879–890.
- Nowak RM , Parker JM , Silverman RA , et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14–20. doi:https://doi.org/10.1016/j.ajem.2014.09.036.
- Park HS , Kim MK , Imai N , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in south korea and japan. Int Arch Allergy Immunol. 2016;169(3):135–145. [doi]. doi:https://doi.org/10.1159/000444799.
- National Heart, Lung and Blood Institute . Quality assessment of controlled intervention studies. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools (accessed June 16, 2017).
- Higgins JP , Altman DG , Gotzsche PC , et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
- Cabon Y , Molinari N , Marin G , et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: Global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47(1):129–138. doi:https://doi.org/10.1111/cea.12853.
- Wang FP , Liu T , Lan Z , Li SY , Mao H . Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A systematic review and meta-analysis. PLoS One. 2016;11(11):e0166833. doi:https://doi.org/10.1371/journal.pone.0166833.
- Wang FP , Xiong XF , Liu T , Li SY , Cheng DY , Mao H . Anti-interleukin 5 therapy for eosinophilic asthma: A meta-analysis of randomized clinical trials. Clin Rev Allergy Immunol. 2016;54(2):318–330. doi:https://doi.org/10.1007/s12016-016-8588-x.
- Ando K , Tanaka A , Yokoe T , Ohnishi T , Inoue S , Sagara H . Meta-analysis of low-versus high-dose benralizumab in adults with uncontrolled eosinophilic asthma. Showa Univ J Med Sci. 2016;28(4):337–347.
- Ferguson GT , FitzGerald JM , Bleecker ER , et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2017;5(7):568–576. doi: S2213-2600(17)30190-X [pii].